Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114578 | 1.00 | — | — | |
| SCHEMBL16095480 | 1.00 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL820047 | 0.95 | — | — | |
| SCHEMBL15545823 | 0.89 | — | — | |
| SCHEMBL2373861 | 0.89 | — | — | |
| SCHEMBL16702853 | 0.89 | — | — | |
| SCHEMBL5945223 | 0.86 | — | — | |
| SCHEMBL626060 | 0.84 | — | — | |
| SCHEMBL4254341 | 0.83 | — | — | |
| SCHEMBL165910 | 0.83 | TRPA1 (0.31) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6667341-B2 | Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters; anticancer agents, hemological disorders, and inherited metabolic disorders | BEACON LABORATORIES, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030171409-A1 | Novel delta dicarbonyl compounds and methods for using the same | BEACON LABORATORIES, INC, A DELAWARE CORPORATION | 2003-09-11 | — | — | US | disclosed |
| US-6562995-B1 | Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters are disclosed. The novel compounds have two carbonyl groups connected by a linking moiety having | BEACON LABORATORIES, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20020137775-A1 | Novel delta dicarbonyl compounds and methods for using the same | ERRANT GENE THERAPEUTICS, LLC | 2002-09-26 | — | — | US | disclosed |
| EP-1216986-A2 | Novel delta dicarbonyl compounds and methods for using same | Beacon Laboratories, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171409-A1 | Novel delta dicarbonyl compounds and methods for using the same | HCCS, CPS1, ACAA2 | TRPA1 4700/4885 |
| US-20020137775-A1 | Novel delta dicarbonyl compounds and methods for using the same | HCCS, CPS1, ACAA2 | TRPA1 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.